Osteo-promoting activity of OSTEOPLANT ANGIOSTAD in vitro.
OBJECTIVE
There is an increasing need for an appropriate and readily-available material to reconstruct large bone defects, one of the most significant problems in the dental and maxillo-facial fields. The in vitro study examines the effects of OSTEOPLANT ANGIOSTAD, a product developed to increase osteoinductivity.


METHODS
The product's biological properties were assessed by examining: the viability of cultured bone-marrow mesenchymal stem cells (MSC) through the methylthiazol tetrazolium assay; transforming growth factor (TGF)-b release by these cells through the enzyme-linked immunosorbent assay (ELISA) and the migration capacity of MSC and endothelial cells, by the in vitro wound closure test and transwell-migration assay, respectively.


RESULTS
OSTEOPLANT ANGIOSTAD preserved MSC's viability and improved their capacity to release TGF-b1. It also increased in vitro wound healing by MSC and migration of endothelial cells.


CONCLUSIONS
The results show that, since it increases the production by MSC of proangiogenic factors such as TGF-beta and promotes endothelial cell migration, OSTEOPLANT ANGIOSTAD may be an appropriate adjunct to accelerate the osteointegration of bone substitutes.
Bellone
G
G
Department of Clinical Physiopathology, University of Turin, Italy. graziella.bellone@unito.it
Scirelli
T
T
Emanuelli
G
G
D002478:Cells, Cultured; D024042:Collagen Type I / Q000494:pharmacology*; D042783:Endothelial Cells / Q000187:drug effects; D006801:Humans; D059630:Mesenchymal Stem Cells / Q000187:drug effects; D010012:Osteogenesis / Q000187:drug effects*
D024042:Collagen Type I; C532633:osteoplant angiostad